Blocking polyamines to enhance immune responses in head and neck cancer
Polyamine blockade and anti-tumor immunity in head and neck squamous cell carcinoma
This study is looking at whether stopping the production of certain substances in tumors can help boost the immune system's ability to fight head and neck cancer, which could lead to safer and more effective treatments for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11112790 on NIH RePORTER |
What this research studies
This research investigates how blocking polyamine metabolism can improve the immune response against head and neck squamous cell carcinoma (HNSC). The approach focuses on understanding how high levels of polyamines in the tumor microenvironment suppress T cell function and antigen presentation. By inhibiting polyamine synthesis and uptake, the study aims to promote anti-tumor immunity while reducing inflammation. This could lead to the development of less toxic and more effective therapies for patients with HNSC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with head and neck squamous cell carcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancers or those who do not have head and neck squamous cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted therapies that enhance the immune system's ability to fight head and neck cancer.
How similar studies have performed: Previous research has shown promise in targeting immune responses in cancer treatment, suggesting that this approach could be effective, although it is still an emerging area of study.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Harbison, Richard Alexander — Washington University
- Study coordinator: Harbison, Richard Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.